The global GLP-1 agonists market, valued at $11.99 billion in 2025, is projected for steady growth driven by rising diabetes prevalence and demand for effective glucose-lowering therapies. Learn about market trends, key players (Novo Nordisk, Eli Lilly, Sanofi), and regional insights in our comprehensive analysis.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.